Work

MEK Inhibitors in Combination with Immune Checkpoint Inhibition: Should we be Chasing Colorectal Cancer or the KRAS Mutant Cancer

Year: 2017

Type: article

Abstract: In the past few years, immunotherapy, particularly immune checkpoint inhibitors, have redefi ned standard of care cancer treatment for numerous malignancies. However, despite the wealth of promising data and great enthusiasm, the vast majority of cancer patients still fail to respond to these therapies as single agents.

Source: Global Journal of Cancer Therapy

DOI: 10.17352/gjct.000019

Author: J Strauss

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W2783589975